Natera Inc (NASDAQ: NTRA) is a diagnostics company that develops and applies proprietary cell-free DNA (cfDNA) molecular and bioinformatics technology to genetic testing across a range of serious conditions. The company generates revenue by processing genetic tests for patients, with results delivered to clinicians, and bills insurers, government payers, and patients on a per-test transactional basis. Natera's cfDNA platform combines novel molecular assays, capable of measuring many informative genomic regions from samples as small as a single cell, with statistical algorithms that draw on broader scientific data to identify genetic variations with high accuracy. The company positions itself as applying personalized genetic testing to change disease management, with applications spanning prenatal health, oncology, and organ health. Natera is listed on the Nasdaq Stock Market and filed its FY2025 10-K on February 27, 2026.

Revenue model

Per-test transactional revenue model. Natera processes genetic tests and bills insurers, government payers, and patients for each test performed. No subscription or licensing revenue structure is described in the available filing excerpts.

Products and services

Cell-free DNA (cfDNA) based genetic tests using proprietary molecular assays and statistical bioinformatics algorithms. Tests cover a wide range of serious conditions including prenatal, oncology, and organ health applications, as described in the FY2025 10-K filed February 27, 2026.

Customers and end markets

Clinicians and patients are the primary end users, with reimbursement from insurers and government payers. End markets include prenatal diagnostics, oncology, and organ health, per the FY2025 10-K filed February 27, 2026.

Value-chain role

Diagnostics laboratory and bioinformatics technology developer. Natera sits between sample collection (by clinicians) and clinical decision-making, processing cfDNA samples and delivering genetic test results.

Geographic exposure

The filing describes operations aimed at changing disease management worldwide, but specific geographic revenue breakdowns are not provided in the available excerpts from the FY2025 10-K.

Source: SEC 10-K, filed 2026-02-27

Industry: Services-Medical Laboratories Peers: Cerevel Therapeutics Holdings, Inc. Blueprint Medicines Corp Cytokinetics Inc Exelixis Inc Global Blood Therapeutics, Inc. Halozyme Therapeutics Inc Intellia Therapeutics Inc Mirati Therapeutics, Inc.